Global Dacryocystitis Treatment Market
Global Dacryocystitis Treatment Market

Dacryocystitis Treatment Comprehensive Study by Administration (Oral, Parenteral), Category (Acute Dacryocystitis, Congenital Dacryocystitis, Acquired Dacryocystitis, Chronic Dacryocystitis), End Use (Hospitals, Clinics, Others), Distribution (Hospital Dispensary, Retail Pharmacy, Third Party Websites, Others) Players and Region - Global Market Outlook to 2026

Dacryocystitis Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jul 2021 Edition 232 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Dacryocystitis Treatment Market Scope
Dacryocystitis is a clinical condition characterised by inflammation of the lacrimal sac. Infections are uncommon and can be either acute or persistent. Acute dacryoadenitis is characterised by painful erythema and swelling in the lateral portion of the upper lid. It can cause preseptal or orbital cellulitis, as well as suppuration into an abscess. The clinical picture's signs and symptoms may differ depending on the cause. Many research have been conducted on the basis of clinical diagnosis to enhance our understanding of the etiopathogenic mechanisms that lead to dacryocystitis and, as a result, to offer an appropriate, effective therapy for patients.

The Dacryocystitis Treatment market study is segmented and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA estimates that United States & Indian Players will contribute to the maximum growth of Global Dacryocystitis Treatment market throughout the predicted period.

Pfizer Inc. (United States), Abbott Laboratories (United States), Glaxosmithkline Plc (United Kingdom), Mylan Inc. (United States), Cipla Limited (India), FCI Ophthalmics (United States), Aurolab (India), Kaneka Corporation (Japan), Gunther Weiss Scientific Glass (United States) and Bess Medizintechnik GmbH (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Aurobindo Pharma (India), Nosch Labs Private Limited (India) and Orex Pharma Pvt Ltd (India).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Dacryocystitis Treatment market by Type, Application and Region.

On the basis of geography, the market of Dacryocystitis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

On 21st June, 2019 - Ocular Therapeutix Received FDA Approval of its Supplemental New Drug Application (sNDA) for DEXTENZA (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use), a Preservative-Free, Resorbable Hydrogel, for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery.


Market Trend
  • Surge in Number of Collaboration Activities in Therapeutics

Market Drivers
  • Increasing Preference for Biological Therapies
  • Prevalence of Dacryocystitis
  • Technical Progress in Biotechnology

Opportunities
  • Increasing Demand Across Emerging Regions
  • High Expenditure Across Healthcare & Pharma Infrastructure

Restraints
  • Lack of Awareness
  • High Initial Investment

Challenges
  • Market Penetration Across New Regions


Key Target Audience
Dacryocystitis Treatment Medication Manufacturers, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently Asked Questions (FAQ):

1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Dacryocystitis Treatment Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Administration
  • Oral
  • Parenteral

By Category
  • Acute Dacryocystitis
  • Congenital Dacryocystitis
  • Acquired Dacryocystitis
  • Chronic Dacryocystitis

By End Use
  • Hospitals
  • Clinics
  • Others

By Distribution
  • Hospital Dispensary
  • Retail Pharmacy
  • Third Party Websites
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Preference for Biological Therapies
      • 3.2.2. Prevalence of Dacryocystitis
      • 3.2.3. Technical Progress in Biotechnology
    • 3.3. Market Challenges
      • 3.3.1. Market Penetration Across New Regions
    • 3.4. Market Trends
      • 3.4.1. Surge in Number of Collaboration Activities in Therapeutics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dacryocystitis Treatment, by Administration, Category, End Use, Distribution and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Dacryocystitis Treatment (Value)
      • 5.2.1. Global Dacryocystitis Treatment by: Administration (Value)
        • 5.2.1.1. Oral
        • 5.2.1.2. Parenteral
      • 5.2.2. Global Dacryocystitis Treatment by: Category (Value)
        • 5.2.2.1. Acute Dacryocystitis
        • 5.2.2.2. Congenital Dacryocystitis
        • 5.2.2.3. Acquired Dacryocystitis
        • 5.2.2.4. Chronic Dacryocystitis
      • 5.2.3. Global Dacryocystitis Treatment by: End Use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Dacryocystitis Treatment by: Distribution (Value)
        • 5.2.4.1. Hospital Dispensary
        • 5.2.4.2. Retail Pharmacy
        • 5.2.4.3. Third Party Websites
        • 5.2.4.4. Others
      • 5.2.5. Global Dacryocystitis Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Dacryocystitis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Glaxosmithkline Plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cipla Limited (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. FCI Ophthalmics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Aurolab (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Kaneka Corporation (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Gunther Weiss Scientific Glass (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bess Medizintechnik GmbH (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Dacryocystitis Treatment Sale, by Administration, Category, End Use, Distribution and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Dacryocystitis Treatment (Value)
      • 7.2.1. Global Dacryocystitis Treatment by: Administration (Value)
        • 7.2.1.1. Oral
        • 7.2.1.2. Parenteral
      • 7.2.2. Global Dacryocystitis Treatment by: Category (Value)
        • 7.2.2.1. Acute Dacryocystitis
        • 7.2.2.2. Congenital Dacryocystitis
        • 7.2.2.3. Acquired Dacryocystitis
        • 7.2.2.4. Chronic Dacryocystitis
      • 7.2.3. Global Dacryocystitis Treatment by: End Use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Dacryocystitis Treatment by: Distribution (Value)
        • 7.2.4.1. Hospital Dispensary
        • 7.2.4.2. Retail Pharmacy
        • 7.2.4.3. Third Party Websites
        • 7.2.4.4. Others
      • 7.2.5. Global Dacryocystitis Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dacryocystitis Treatment: by Administration(USD Million)
  • Table 2. Dacryocystitis Treatment Oral , by Region USD Million (2015-2020)
  • Table 3. Dacryocystitis Treatment Parenteral , by Region USD Million (2015-2020)
  • Table 4. Dacryocystitis Treatment: by Category(USD Million)
  • Table 5. Dacryocystitis Treatment Acute Dacryocystitis , by Region USD Million (2015-2020)
  • Table 6. Dacryocystitis Treatment Congenital Dacryocystitis , by Region USD Million (2015-2020)
  • Table 7. Dacryocystitis Treatment Acquired Dacryocystitis , by Region USD Million (2015-2020)
  • Table 8. Dacryocystitis Treatment Chronic Dacryocystitis , by Region USD Million (2015-2020)
  • Table 9. Dacryocystitis Treatment: by End Use(USD Million)
  • Table 10. Dacryocystitis Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 11. Dacryocystitis Treatment Clinics , by Region USD Million (2015-2020)
  • Table 12. Dacryocystitis Treatment Others , by Region USD Million (2015-2020)
  • Table 13. Dacryocystitis Treatment: by Distribution(USD Million)
  • Table 14. Dacryocystitis Treatment Hospital Dispensary , by Region USD Million (2015-2020)
  • Table 15. Dacryocystitis Treatment Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 16. Dacryocystitis Treatment Third Party Websites , by Region USD Million (2015-2020)
  • Table 17. Dacryocystitis Treatment Others , by Region USD Million (2015-2020)
  • Table 18. South America Dacryocystitis Treatment, by Country USD Million (2015-2020)
  • Table 19. South America Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 20. South America Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 21. South America Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 22. South America Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 23. Brazil Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 24. Brazil Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 25. Brazil Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 26. Brazil Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 27. Argentina Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 28. Argentina Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 29. Argentina Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 30. Argentina Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 31. Rest of South America Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 32. Rest of South America Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 33. Rest of South America Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 34. Rest of South America Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 35. Asia Pacific Dacryocystitis Treatment, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 37. Asia Pacific Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 38. Asia Pacific Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 39. Asia Pacific Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 40. China Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 41. China Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 42. China Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 43. China Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 44. Japan Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 45. Japan Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 46. Japan Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 47. Japan Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 48. India Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 49. India Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 50. India Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 51. India Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 52. South Korea Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 53. South Korea Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 54. South Korea Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 55. South Korea Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 56. Taiwan Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 57. Taiwan Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 58. Taiwan Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 59. Taiwan Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 60. Australia Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 61. Australia Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 62. Australia Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 63. Australia Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 68. Europe Dacryocystitis Treatment, by Country USD Million (2015-2020)
  • Table 69. Europe Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 70. Europe Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 71. Europe Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 72. Europe Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 73. Germany Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 74. Germany Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 75. Germany Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 76. Germany Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 77. France Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 78. France Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 79. France Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 80. France Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 81. Italy Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 82. Italy Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 83. Italy Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 84. Italy Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 85. United Kingdom Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 86. United Kingdom Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 87. United Kingdom Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 88. United Kingdom Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 89. Netherlands Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 90. Netherlands Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 91. Netherlands Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 92. Netherlands Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 93. Rest of Europe Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 94. Rest of Europe Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 95. Rest of Europe Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 96. Rest of Europe Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 97. MEA Dacryocystitis Treatment, by Country USD Million (2015-2020)
  • Table 98. MEA Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 99. MEA Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 100. MEA Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 101. MEA Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 102. Middle East Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 103. Middle East Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 104. Middle East Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 105. Middle East Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 106. Africa Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 107. Africa Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 108. Africa Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 109. Africa Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 110. North America Dacryocystitis Treatment, by Country USD Million (2015-2020)
  • Table 111. North America Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 112. North America Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 113. North America Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 114. North America Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 115. United States Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 116. United States Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 117. United States Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 118. United States Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 119. Canada Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 120. Canada Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 121. Canada Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 122. Canada Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 123. Mexico Dacryocystitis Treatment, by Administration USD Million (2015-2020)
  • Table 124. Mexico Dacryocystitis Treatment, by Category USD Million (2015-2020)
  • Table 125. Mexico Dacryocystitis Treatment, by End Use USD Million (2015-2020)
  • Table 126. Mexico Dacryocystitis Treatment, by Distribution USD Million (2015-2020)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Dacryocystitis Treatment: by Administration(USD Million)
  • Table 138. Dacryocystitis Treatment Oral , by Region USD Million (2021-2026)
  • Table 139. Dacryocystitis Treatment Parenteral , by Region USD Million (2021-2026)
  • Table 140. Dacryocystitis Treatment: by Category(USD Million)
  • Table 141. Dacryocystitis Treatment Acute Dacryocystitis , by Region USD Million (2021-2026)
  • Table 142. Dacryocystitis Treatment Congenital Dacryocystitis , by Region USD Million (2021-2026)
  • Table 143. Dacryocystitis Treatment Acquired Dacryocystitis , by Region USD Million (2021-2026)
  • Table 144. Dacryocystitis Treatment Chronic Dacryocystitis , by Region USD Million (2021-2026)
  • Table 145. Dacryocystitis Treatment: by End Use(USD Million)
  • Table 146. Dacryocystitis Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 147. Dacryocystitis Treatment Clinics , by Region USD Million (2021-2026)
  • Table 148. Dacryocystitis Treatment Others , by Region USD Million (2021-2026)
  • Table 149. Dacryocystitis Treatment: by Distribution(USD Million)
  • Table 150. Dacryocystitis Treatment Hospital Dispensary , by Region USD Million (2021-2026)
  • Table 151. Dacryocystitis Treatment Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 152. Dacryocystitis Treatment Third Party Websites , by Region USD Million (2021-2026)
  • Table 153. Dacryocystitis Treatment Others , by Region USD Million (2021-2026)
  • Table 154. South America Dacryocystitis Treatment, by Country USD Million (2021-2026)
  • Table 155. South America Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 156. South America Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 157. South America Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 158. South America Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 159. Brazil Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 160. Brazil Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 161. Brazil Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 162. Brazil Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 163. Argentina Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 164. Argentina Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 165. Argentina Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 166. Argentina Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 167. Rest of South America Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 168. Rest of South America Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 169. Rest of South America Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 170. Rest of South America Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 171. Asia Pacific Dacryocystitis Treatment, by Country USD Million (2021-2026)
  • Table 172. Asia Pacific Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 173. Asia Pacific Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 174. Asia Pacific Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 175. Asia Pacific Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 176. China Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 177. China Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 178. China Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 179. China Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 180. Japan Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 181. Japan Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 182. Japan Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 183. Japan Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 184. India Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 185. India Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 186. India Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 187. India Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 188. South Korea Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 189. South Korea Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 190. South Korea Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 191. South Korea Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 192. Taiwan Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 193. Taiwan Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 194. Taiwan Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 195. Taiwan Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 196. Australia Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 197. Australia Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 198. Australia Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 199. Australia Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 204. Europe Dacryocystitis Treatment, by Country USD Million (2021-2026)
  • Table 205. Europe Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 206. Europe Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 207. Europe Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 208. Europe Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 209. Germany Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 210. Germany Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 211. Germany Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 212. Germany Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 213. France Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 214. France Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 215. France Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 216. France Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 217. Italy Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 218. Italy Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 219. Italy Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 220. Italy Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 221. United Kingdom Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 222. United Kingdom Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 223. United Kingdom Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 224. United Kingdom Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 225. Netherlands Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 226. Netherlands Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 227. Netherlands Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 228. Netherlands Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 229. Rest of Europe Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 230. Rest of Europe Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 231. Rest of Europe Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 232. Rest of Europe Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 233. MEA Dacryocystitis Treatment, by Country USD Million (2021-2026)
  • Table 234. MEA Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 235. MEA Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 236. MEA Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 237. MEA Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 238. Middle East Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 239. Middle East Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 240. Middle East Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 241. Middle East Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 242. Africa Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 243. Africa Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 244. Africa Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 245. Africa Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 246. North America Dacryocystitis Treatment, by Country USD Million (2021-2026)
  • Table 247. North America Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 248. North America Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 249. North America Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 250. North America Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 251. United States Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 252. United States Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 253. United States Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 254. United States Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 255. Canada Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 256. Canada Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 257. Canada Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 258. Canada Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 259. Mexico Dacryocystitis Treatment, by Administration USD Million (2021-2026)
  • Table 260. Mexico Dacryocystitis Treatment, by Category USD Million (2021-2026)
  • Table 261. Mexico Dacryocystitis Treatment, by End Use USD Million (2021-2026)
  • Table 262. Mexico Dacryocystitis Treatment, by Distribution USD Million (2021-2026)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dacryocystitis Treatment: by Administration USD Million (2015-2020)
  • Figure 5. Global Dacryocystitis Treatment: by Category USD Million (2015-2020)
  • Figure 6. Global Dacryocystitis Treatment: by End Use USD Million (2015-2020)
  • Figure 7. Global Dacryocystitis Treatment: by Distribution USD Million (2015-2020)
  • Figure 8. South America Dacryocystitis Treatment Share (%), by Country
  • Figure 9. Asia Pacific Dacryocystitis Treatment Share (%), by Country
  • Figure 10. Europe Dacryocystitis Treatment Share (%), by Country
  • Figure 11. MEA Dacryocystitis Treatment Share (%), by Country
  • Figure 12. North America Dacryocystitis Treatment Share (%), by Country
  • Figure 13. Global Dacryocystitis Treatment share by Players 2020 (%)
  • Figure 14. Global Dacryocystitis Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Dacryocystitis Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 20. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 21. Glaxosmithkline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. Glaxosmithkline Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 23. Mylan Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Mylan Inc. (United States) Revenue: by Geography 2020
  • Figure 25. Cipla Limited (India) Revenue, Net Income and Gross profit
  • Figure 26. Cipla Limited (India) Revenue: by Geography 2020
  • Figure 27. FCI Ophthalmics (United States) Revenue, Net Income and Gross profit
  • Figure 28. FCI Ophthalmics (United States) Revenue: by Geography 2020
  • Figure 29. Aurolab (India) Revenue, Net Income and Gross profit
  • Figure 30. Aurolab (India) Revenue: by Geography 2020
  • Figure 31. Kaneka Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Kaneka Corporation (Japan) Revenue: by Geography 2020
  • Figure 33. Gunther Weiss Scientific Glass (United States) Revenue, Net Income and Gross profit
  • Figure 34. Gunther Weiss Scientific Glass (United States) Revenue: by Geography 2020
  • Figure 35. Bess Medizintechnik GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Bess Medizintechnik GmbH (Germany) Revenue: by Geography 2020
  • Figure 37. Global Dacryocystitis Treatment: by Administration USD Million (2021-2026)
  • Figure 38. Global Dacryocystitis Treatment: by Category USD Million (2021-2026)
  • Figure 39. Global Dacryocystitis Treatment: by End Use USD Million (2021-2026)
  • Figure 40. Global Dacryocystitis Treatment: by Distribution USD Million (2021-2026)
  • Figure 41. South America Dacryocystitis Treatment Share (%), by Country
  • Figure 42. Asia Pacific Dacryocystitis Treatment Share (%), by Country
  • Figure 43. Europe Dacryocystitis Treatment Share (%), by Country
  • Figure 44. MEA Dacryocystitis Treatment Share (%), by Country
  • Figure 45. North America Dacryocystitis Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Pfizer Inc. (United States)
  • Abbott Laboratories (United States)
  • Glaxosmithkline Plc (United Kingdom)
  • Mylan Inc. (United States)
  • Cipla Limited (India)
  • FCI Ophthalmics (United States)
  • Aurolab (India)
  • Kaneka Corporation (Japan)
  • Gunther Weiss Scientific Glass (United States)
  • Bess Medizintechnik GmbH (Germany)
Additional players considered in the study are as follows:
Aurobindo Pharma (India) , Nosch Labs Private Limited (India) , Orex Pharma Pvt Ltd (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation